Catalyst Wire Dossier Catalyst Wire Dossier

Selpercatinib (Retevmo)

selpercatinib · Eli Lilly and Company
Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for Selpercatinib (Retevmo), covering 2025-09-16 to 2025-09-16. Get the full timeline:

Most recent: Clinical Trial Update: A Drug Drug Interaction (DDI) Study of Selpercatinib (LY3527723) and Rosuvastatin in Healthy Participants [Phase 1]

See pricing